We analyzed the phenotypic and functional (IFNγ production, and Granzyme B (GrzB) cytotoxic granule marker expression) profile of peripheral blood T lymphocyte subsets ("conventional" CD4<sup>+</sup> and CD8<sup>+</sup>, FOXP3<sup>+</sup>CD25<sup>bright</sup> Treg, and "innate-like" CD56<sup>+</sup>) in DLBCL patients at diagnosis, and assessed the long-term impact of R-CHOP chemoimmunotherapy, in a prospective study.
Interestingly, exogenous IL-10 significantly improved the survival of DLBCL CD8<sup>+</sup> T cells, and resulted in significantly higher IFN-γ, ganzyme A and granzyme B expression in the absence of CD19<sup>+</sup> tumor cells, and significantly improved CD8<sup>+</sup> T cell-mediated specific lysis of CD19<sup>+</sup> tumor cells.